tag pharma-sales 
pharmaphorum
MAY 24, 2021
It is a newer concept for pharma marketers, however, who are now turning to modular solutions in response to the accelerated demand for content over the past year. Robb DeFilippis, managing director, life sciences, for end-to-end global creative production and sourcing partner Tag in the Americas agrees. About the interviewee.
pharmaphorum
AUGUST 17, 2020
N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Nevertheless, the advent of COVID-19 is forcing pharma, and many other sectors, to make some radical changes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 19, 2021
So too are the sales figures. billion in vaccine sales this year. Indeed, the price tags for Pfizer’s and Moderna’s jabs are substantial. This sales strategy contrasts to AstraZeneca, which pledged to provide its vaccine on a not-for-profit basis until the pandemic ends. billion in covid vaccine sales in 2021.
pharmaphorum
NOVEMBER 16, 2021
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. The drug made almost $17 million in US sales in the third quarter.
pharmaphorum
SEPTEMBER 15, 2020
Companies like prescription glasses firm Warby Parker, shoe brand Rothy’s and tele-dentistry’s SmileDirectClub have grown up in today’s digitally native environment and can offer some key pointers for pharma. As part of this, a number of big pharma companies are also racing to develop a safe and effective vaccine for the coronavirus.
pharmaphorum
JANUARY 24, 2022
IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise.
pharmaphorum
MARCH 23, 2022
Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).
Expert insights. Personalized for you.
89 
Let's personalize your content